Immunotherapy drug sintilimab takes on rare blood vessel cancer

NCT ID NCT05026736

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether sintilimab, an immunotherapy drug, can help control angiosarcoma—a rare cancer of the blood vessels—that is advanced, has spread, or has returned. Participants receive sintilimab intravenously, and the study measures how many have no cancer growth after nine treatment cycles. The trial enrolls adults who have already tried chemotherapy without success or cannot tolerate it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an immunotherapy drug called sintilimab, which helps the immune system attack cancer cells
What this could lead to: If successful, this could offer a new treatment option for people with angiosarcoma who have not responded to chemotherapy.
What could go wrong: This is a small, early-phase trial with only 6 participants, so results may not apply broadly. The drug may cause immune-related side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates